LON:AMYT

Amryt Pharma (AMYT) Share Forecast, Price & News

GBX 143

-19.00 (-11.73%)

(As of 01/10/2022)

Compare

Today's Range: 143
▼
155
50-Day Range: 143
▼
143
52-Week Range: 135
▼
230

Volume: 90,727 shs
Average Volume: 469,552 shs
Market Capitalization: £457.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Insider Trades Headlines

About Amryt Pharma (LON:AMYT) Stock

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

AMYT Stock News Headlines

May 28, 2023 | americanbankingnews.com

Amryt Pharma (LON:AMYT) Stock Passes Below 50 Day Moving Average of $143.00

April 23, 2023 | americanbankingnews.com

Amryt Pharma (LON:AMYT) Shares Cross Below 50 Day Moving Average of $143.00

May 31, 2023 | Edge On The Street (Ad)

Soaring EV Industry Keeps Investor Focus on Lithium

The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.

March 22, 2023 | finance.yahoo.com

Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici

January 16, 2023 | msn.com

Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma

January 10, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amryt Pharma Plc Buyout

January 9, 2023 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBO

January 9, 2023 | technews.tmcnet.com

AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders

May 31, 2023 | Edge On The Street (Ad)

Soaring EV Industry Keeps Investor Focus on Lithium

The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.

January 8, 2023 | news.yahoo.com

Italy's Chiesi Farmaceutici to buy Amryt Pharma in a $1.48 billion deal

January 8, 2023 | au.finance.yahoo.com

Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc

December 5, 2022 | ca.finance.yahoo.com

European Commission approves Mycapssa® for the treatment of Acromegaly

October 31, 2022 | nz.finance.yahoo.com

Amryt Supports Acromegaly Awareness Day 2022

October 17, 2022 | finance.yahoo.com

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)

October 15, 2022 | seekingalpha.com

AMYT Amryt Pharma plc

August 6, 2022 | seekingalpha.com

Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates

July 30, 2022 | morningstar.com

Amryt Pharma PLC ADR Stock Quote AMYT

June 27, 2022 | seekingalpha.com

Amryt Pharma appoints Dr Tracy Cunningham as Chief Medical Officer

June 25, 2022 | marketwatch.com

Amryt to Pursue Formal FDA Resolution for Oleogel-S10 >AMYT

June 24, 2022 | finance.yahoo.com

Filsuvez's European Approval Adds Growth Driver For Amryt Pharma

June 24, 2022 | nasdaq.com

Amryt Pharma To Submit Formal Dispute Resolution Request For Oleogel-S10 NDA

May 17, 2022 | finance.yahoo.com

Amryt Announces Details of EMA Contingent Value Rights Payment

May 11, 2022 | uk.finance.yahoo.com

Amryt Announces New Patent for Mycapssa®

May 8, 2022 | seekingalpha.com

Amryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call Transcript

April 22, 2022 | seekingalpha.com

Amryt stock rises 10% as EMA panel backs approval of Filsuvez to treat skin disorder in EU

April 13, 2022 | finance.yahoo.com

Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:AMYT
Previous Symbol: LON:FAST
CUSIP: N/A
CIK: N/A
Web: www.amrytpharma.com
Phone: +44-20-34155730
Fax: N/A
Employees: 2,020
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 66.05
Current Ratio: 1.80
Quick Ratio: 1.14

Sales & Book Value

Annual Sales: £210.24 million
Price / Sales: 2.17
Cash Flow: GBX 38.90 per share
Price / Cash Flow: 3.68
Book Value: GBX 96.60 per share
Price / Book: 1.48

Miscellaneous

Outstanding Shares: 319,657,000
Free Float: N/A
Market Cap: £457.11 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Joseph A. Wiley (Age 50)
CEO & Director
Comp: $1.72M

Mr. Rory P. Nealon (Age 53)
CFO, COO & Company Sec.
Comp: $931k

Ms. Elizabeth Varki Jobes J.D. (Age 54)
Sr. VP & Global Chief Compliance Officer

Mr. John McEvoy
Gen. Counsel

Mr. Stephen Joyce
VP of Global Marketing

Ms. Julie Eastwood
Head of HR

Ms. Derval O'Carroll
Head of Regulatory Affairs

Mr. Gerry Gilligan
Head of Manufacturing Supply Chain

Dr. Mark Sumeray (Age 55)
Chief Medical Officer

Mr. David Allmond
Chief Commercial Officer

Key Competitors

View All Competitors

AMYT Stock - Frequently Asked Questions

How have AMYT shares performed in 2023?: Amryt Pharma's stock was trading at GBX 143 at the start of the year. Since then, AMYT stock has increased by 0.0% and is now trading at GBX 143.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Amryt Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta PLC (CPT.L) (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL), Bowleven (BLVN), BTG (BTG) and Cavium (CAVM).
What is Amryt Pharma's stock symbol?: Amryt Pharma trades on the London Stock Exchange (LON) under the ticker symbol "AMYT."
How do I buy shares of Amryt Pharma?: Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Amryt Pharma's stock price today?: One share of AMYT stock can currently be purchased for approximately GBX 143.
How much money does Amryt Pharma make?: Amryt Pharma (LON:AMYT) has a market capitalization of £457.11 million and generates £210.24 million in revenue each year.
How many employees does Amryt Pharma have?: The company employs 2,020 workers across the globe.
How can I contact Amryt Pharma?: Amryt Pharma's mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The official website for the company is www.amrytpharma.com. The company can be reached via phone at +44-20-34155730.

This page (LON:AMYT) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial